We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
Read MoreHide Full Article
Key Takeaways
Tempus AI acquired Paige for $81.25M, gaining 7M pathology images and FDA-cleared AI tools.
The Deep 6 AI deal expanded Tempus' reach to 30M patient records across 750 healthcare providers.
Ambry Genetics' acquisition broadened Tempus' AI-driven offerings into genetics and multiple specialties.
Last Friday, Tempus AI, Inc. (TEM - Free Report) announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition, valued at $81.25 million, is expected to allow Tempus to grow its dataset and expand its experienced technical team. Paige brings nearly 7 million digitized pathology slide images and associated clinical and molecular data that are carefully labeled. Paige has already created the first AI tool cleared by the FDA for pathology. These factors will help Tempus establish a strong footprint in digital pathology with an industry-leading technology portfolio.
Additionally, in March, Tempus acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep 6 AI works with over 750 healthcare providers and has access to medical records from more than 30 million patients. By integrating Deep 6 AI’s technology, Tempus significantly expanded its reach and enhanced platforms such as Next, which improves patient care, and TIME, which connects patients to life-saving clinical trials.
Furthermore, earlier this year, Tempus completed the acquisition of Ambry Genetics, a genetic testing company that specializes in hereditary cancer screening and other genetic diseases. Tempus acquired Ambry Genetics with $375 million in cash and $225 million in stock, with $100 million of that stock temporarily locked up for a year. By combining Ambry’s genetic testing strengths with Tempus’ AI and data tools, the latter broadened its healthcare offerings into new areas, like pediatrics, women's health, rare disease, immunology and cardiology.
Acquisitions by TEM’s Peers
In April, NeoGenomics, Inc. (NEO - Free Report) completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. This strengthens NeoGenomics' footprint in the Northeastern United States, expanding its molecular and hematology-oncology testing services. It is expected to drive top-line growth and generate cost synergies, with a positive impact on adjusted EBITDA by 2026.
In 2024, Veracyte, Inc. (VCYT - Free Report) acquired C2i Genomics, Inc. for $70 million in shares, with up to $25 million more, contingent on performance milestones, over two years. The acquisition brought AI-driven, whole-genome minimal residual disease (MRD) capabilities to Veracyte’s novel diagnostics platforms, enabling test expansion from early diagnosis to treatment monitoring and recurrence detection.
TEM Stock Outperforms Industry & Benchmark
Year to date, Tempus AI shares have surged 121.3%, outperforming the industry’s 27% growth and the S&P 500 composite’s 9.8% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 9.04X compared with the industry average of 5.90X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has moved south 3%.
Image: Bigstock
Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership
Key Takeaways
Last Friday, Tempus AI, Inc. (TEM - Free Report) announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition, valued at $81.25 million, is expected to allow Tempus to grow its dataset and expand its experienced technical team. Paige brings nearly 7 million digitized pathology slide images and associated clinical and molecular data that are carefully labeled. Paige has already created the first AI tool cleared by the FDA for pathology. These factors will help Tempus establish a strong footprint in digital pathology with an industry-leading technology portfolio.
Additionally, in March, Tempus acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep 6 AI works with over 750 healthcare providers and has access to medical records from more than 30 million patients. By integrating Deep 6 AI’s technology, Tempus significantly expanded its reach and enhanced platforms such as Next, which improves patient care, and TIME, which connects patients to life-saving clinical trials.
Furthermore, earlier this year, Tempus completed the acquisition of Ambry Genetics, a genetic testing company that specializes in hereditary cancer screening and other genetic diseases. Tempus acquired Ambry Genetics with $375 million in cash and $225 million in stock, with $100 million of that stock temporarily locked up for a year. By combining Ambry’s genetic testing strengths with Tempus’ AI and data tools, the latter broadened its healthcare offerings into new areas, like pediatrics, women's health, rare disease, immunology and cardiology.
Acquisitions by TEM’s Peers
In April, NeoGenomics, Inc. (NEO - Free Report) completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. This strengthens NeoGenomics' footprint in the Northeastern United States, expanding its molecular and hematology-oncology testing services. It is expected to drive top-line growth and generate cost synergies, with a positive impact on adjusted EBITDA by 2026.
In 2024, Veracyte, Inc. (VCYT - Free Report) acquired C2i Genomics, Inc. for $70 million in shares, with up to $25 million more, contingent on performance milestones, over two years. The acquisition brought AI-driven, whole-genome minimal residual disease (MRD) capabilities to Veracyte’s novel diagnostics platforms, enabling test expansion from early diagnosis to treatment monitoring and recurrence detection.
TEM Stock Outperforms Industry & Benchmark
Year to date, Tempus AI shares have surged 121.3%, outperforming the industry’s 27% growth and the S&P 500 composite’s 9.8% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 9.04X compared with the industry average of 5.90X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has moved south 3%.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.